Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.

J Hematol Oncol 2017 02 20;10(1):51. Epub 2017 Feb 20.

Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Austria.

Background: The majority of individuals with acute myeloid leukemia (AML) respond to initial chemotherapy and achieve a complete remission, yet only a minority experience long-term survival because a large proportion of patients eventually relapse with therapy-resistant disease. Relapse therefore represents a central problem in the treatment of AML. Despite this, and in contrast to the extensive knowledge about the molecular events underlying the process of leukemogenesis, information about the mechanisms leading to therapy resistance and relapse is still limited.

Purpose And Content Of Review: Recently, a number of studies have aimed to fill this gap and provided valuable information about the clonal composition and evolution of leukemic cell populations during the course of disease, and about genetic, epigenetic, and gene expression changes associated with relapse. In this review, these studies are summarized and discussed, and the data reported in them are compiled in order to provide a resource for the identification of molecular aberrations recurrently acquired at, and thus potentially contributing to, disease recurrence and the associated therapy resistance. This survey indeed uncovered genetic aberrations with known associations with therapy resistance that were newly gained at relapse in a subset of patients. Furthermore, the expression of a number of protein coding and microRNA genes was reported to change between diagnosis and relapse in a statistically significant manner.

Conclusions: Together, these findings foster the expectation that future studies on larger and more homogeneous patient cohorts will uncover pathways that are robustly associated with relapse, thus representing potential targets for rationally designed therapies that may improve the treatment of patients with relapsed AML, or even facilitate the prevention of relapse in the first place.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-017-0416-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322789PMC
February 2017
2 Reads

Publication Analysis

Top Keywords

therapy resistance
16
relapse
9
resistance relapse
8
myeloid leukemia
8
associated relapse
8
acute myeloid
8
associated therapy
8
identification molecular
4
aberrations recurrently
4
molecular aberrations
4
resource identification
4
provide resource
4
discussed data
4
data reported
4
reported compiled
4
compiled order
4
order provide
4
acquired contributing
4
uncovered genetic
4
genetic aberrations
4

References

(Supplied by CrossRef)

A Almeida et al.
Leuk Res Rep 2016

J Bryan et al.
Drugs Aging 2015

D Sanford et al.
Drugs Aging 2015

M Sanz et al.
Ann Hematol 2016

M Tallman et al.
Blood 2005

J Szer et al.
Hematol Am Soc Hematol Educ Program 2012

F Saraceni et al.
J Hematol Oncol 2016

J Mi et al.
Leukemia 2012

F Lo-Coco et al.
Br J Haematol 2016

S Forman et al.
Blood 2013

D Wiseman et al.
Oncogene 2013

Similar Publications